Clinical trials
for patients

The aim of this study is to determine the DMT and/or RD to further evaluate the intravenous (i.v.) administration of XB002 in monotherapy and polytherapy in patients with advanced malignancies.

Hypoparathyroidism is a very rare disease characterized by the absence or low concentration of parathyroid hormone (PTH) in the blood. Parathyroid hormone (PTH) regulates and maintains the balance of calcium and phosphorus in the body. The most common cause of hypoparathyroidism is the removal or injury of the parathyroid glands during cervical surgery. Other less frequent causes are autoimmune diseases and genetic hypoparathyroidism. Hypoparathyroidism is usually treated with calcium and vitami...

The main objective of the present clinical study is to find out whether patients with advanced stage bile duct cancer, who have already received one line of treatment for their disease, will receive an associated benefit from the combination of mFOLFOX6, bevacizumab and atezolizumab as second-line therapy.

The purpose of this study is to determine the safety and efficacy of an experimental drug called ABBV-552 in the treatment of symptoms of mild Alzheimer's disease.

The aim of this study are: - To test whether ONC201 is effective in treating patients with glioma when given after radiation therapy. - To test how safe and tolerable ONC201 is in patients with glioma compared to using a placebo (a capsule that looks like ONC201, but does not contain any active drug). - To test the extent to which ONC201 can improve quality of life and brain function in glioma patients.

The objective of the research study is to determine whether patients with the specific HER2-enriched subtype will have longer time to disease progression if treated with ribociclib instead of palbociclib.

The purpose of this study is to evaluate the safety and describe the effect of narsoplimab, an "investigational drug", in patients with this type of disease. "Investigational drug" means that the product has not yet been approved by any health authority for sale or use for this indication.

This is a research study to evaluate an investigational new drug called TSR-022. An investigational drug is a drug that has not been authorized by any of the health authorities, including the Spanish Agency of Medicines and Health Products (AEMPS), and is not available for sale or by prescription.

The aim of this study is to evaluate BLYG8824A at different doses to determine if it is safe, find out how the body processes the drug, and determine the effects, positive or negative, that BLYG8824A has on you and your cancer.